Thermo Fisher Scientific announced $600 million in capital investments to expand its bioprocessing production
On Mar. 10, 2021, Thermo Fisher Scientific announced more than $600 million in capital investments to expand its…
-
-
PerkinElmer launched comprehensive solutions for detecting SARS-CoV-2 mutations
On Mar. 9, 2021, PerkinElmer announced the launch of the PerkinElmer COVID-19 Antigen Test for the qualitative detection…
-
NIH scientists used human cerebral organoid to test drug for deadly brain disease
On Mar. 9, 2021, the National Institutes of Health (NIH) announced that approximately two years after establishing a…
-
Agilent completed CE-IVD registration of qRT-PCR In vitro diagnostic kit for SARS-CoV-2 RNA detection
On Mar. 9, 2021, Agilent Technologies announced the launch of a real-time reverse transcription (qRT) PCR-based diagnostic kit…
-
Oragenics announced Material Transfer Agreement with Biodextris for mucosal adjuvant for intranasal COVID-19 vaccine
On Mar. 9, 2021, Oragenics announced it had entered into a material transfer agreement with Biodextris for the…
-
VBI Vaccines announced enrollment in adaptive phase 1/2 study of prophylactic COVID-19 vaccine candidate
On Mar. 9, 2021, VBI Vaccines announced the initiation of enrollment of its Phase 1/2 clinical study of…
-
Luminex submitted joint SARS-CoV-2 and Flu/RSV respiratory panel to FDA for Emergency Use Authorization
On Mar. 10, 2021, Luminex announced that it had submitted an Emergency Use Authorization application to the U.S….
-
NIH launched last phase 3 clinical trial to evaluate safety and effectiveness of blood thinners in adults with COVID-19
On Mar. 8, 2021, the National Institutes of Health (NIH) announced that it had launched the last of…
-
AXIM Biotechnologies successfully completed point-of-care clinical trials on rapid COVID-19 antibody test
On Mar. 8, 2021, AXIM Biotechnologies announced that it had successfully completed point-of-care clinical trials on its much…
-
ImmunityBio and NantKwest began dosing participants in global trials for novel COVID-19 vaccine
On Mar. 8, 2021, ImmunityBio and NantKwest announced that the first cohorts of their South Africa and U.S….
-
AIM ImmunoTech announced first healthy subjects dosed in phase 1 intranasal Ampligen clinical study
On Mar. 8, 2021, AIM ImmunoTech announced that it had dosed the first healthy subjects in its Phase…
-
Baxter and Moderna announced agreement for manufacturing of Moderna COVID-19 vaccine in the US
On Mar. 8, 2021, Baxter and Moderna announced that they had entered into an agreement for Baxter BioPharma…
-
Moderna announced supply agreement to provide 13 million doses of COVID-19 vaccine to the Philippines
On Mar. 6, 2021, Moderna announced a supply agreement with the Government of The Philippines for 13 million doses…
-
Adaptive Biotechnologies announced FDA EUA for T-Detect COVID to confirm prior COVID-19 infection
On Mar. 5, 2020, Adaptive Biotechnologies announced that the U.S. Food and Drug Administration (FDA) had issued an…
-
Abbott’s received FDA EUA for laboratory PCR assay that detects and differentiates SARS-CoV-2, Flu A, Flu B and RSV
On Mar. 5, 2021, Abbott announced the U.S. Food and Drug Administration’s (FDA) Emergency Use Authorization (EUA) for…
-
Ridgeback Biotherapeutics and Merck announced preliminary findings from phase 2a trial of investigational COVID-19 therapeutic
On Mar. 5, 2021, Merck and Ridgeback Biotherapeutics, announced preliminary results from Ridgeback’s Phase 2a randomized, double-blind, placebo-controlled…
-
FDA issued authorization for first molecular non-prescription, at-home test
On Mar. 5, 2021, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the…
-
Moderna announced NDA submitted to import and distribute Moderna’s COVID-19 vaccine candidate in Japan
On Mar. 5, 2021,Takeda Pharmaceutical announced that it has submitted a New Drug Application to the Government of…
-
Recruitment and enrollment began for Innovation Pharma’s phase 2 clinical trial of Brilacidin for COVID-19
On Mar. 5, 2021, Innovation Pharmaceuticals reported that eight sites were participating in the Company’s international Phase 2…
-
Washington State Department of Health provided next-generation genome sequencing
On Mar. 4, 2021, the Washington State Department of Health announced contracts with virology labs at the University…
-
NIH-sponsored ACTIV-3 clinical trial closed enrollment into two sub-studies
On Mar. 4, 2021, the National Institutes of Health (NIH) announced that the ACTIV-3 clinical trial evaluating the…
-
New evidence COVID-19 antibodies, vaccines less effective against variants
On Mar. 4, 2021, researchers at the University School of Medicine in St. Louis announced that three new,…
-
Soligenix announced positive progress in pre-clinical development of its COVID-19 vaccine
On Mar. 4, 2021, Soligenix announced publication of pre-clinical immunogenicity studies for CiVax (heat stable COVID-19 vaccine program)…
-
Luminex received FDA Emergency Use Authorization and CE Mark for expanded NxTAG panel test Including SARS-CoV-2
On Mar. 4, 2021, Luminex announced that it had received Emergency Use Authorization (EUA) from the U.S. Food…
-
MediciNova announced it had discontinued development of a SARS-CoV-2 vaccine for COVID-19
On Mar. 3, 2021, MediciNova announced an update on the development of a SARS-CoV-2 vaccine for COVID-19. MediciNova…
-
Biotechnology | COVID-19 | FDA
Resverlogix published evidence of apabetalone’s beneficial effects on COVID-19
On Mar. 3, 2021, Resverlogix and QIMR Berghofer Medical Research Institute announced the publishing of an article providing…
-
Biotechnology | COVID-19 | Disease | Oncology
Men, older adults and smokers more prone to infection by SARS-CoV-2
On Mar. 3, 2021, TGen, an affiliate of City of Hope announced that an in-depth analysis of the…
-
Pfizer-BioNTech’s COVID-19 vaccine arrived in Rwanda
On Mar. 3, 2021, Pfizer and BioNTech, in partnership with UNICEF, announced the arrival of the first doses…
-
NIH launched effort to understand MIS-C, range of SARS-CoV-2 effects on children
On Mar. 2, 2021, the National Institutes of Health (NIH), announced that it had launched a research effort…
-
Innovation Pharma announced publication in Journal Viruses on the anti-SARS-CoV-2 properties of brilacidin
On Mar. 2, 2021, Innovation Pharmaceuticals reported that eight sites were participating in the Companyﾒs international Phase 2…
